Prescription medicine

Anidulafungin Brand names: Eraxis

Anidulafungin (Eraxis) is a prescription medicine with an FDA approval on record since 2006. No generic is listed in FDA's NDC Directory.

No generic listed

Check it at the source: the anidulafungin FDA label on DailyMed (effective August 19, 2025, Roerig); the NDA 21632 record on Drugs@FDA; every anidulafungin label on DailyMed.

Highlights of the record

FDA label of August 19, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

From the label: indications and usage
ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections:
Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 )
Esophageal candidiasis in adults ( 1.2 ) Limitations of use
ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and men

Forms and strengths

50 mg/15ml
100 mg/30ml

Injection (powder) (lyophilized) for solution.

On the market

Earliest approval on file: February 17, 2006 Eraxis, Vicuron Holdings; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC): Not in the survey
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 1,600 through July 30, 2026

What is anidulafungin used for?

From the label: indications and usage
ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections:
Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 )
Esophageal candidiasis in adults ( 1.2 ) Limitations of use
ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 )
ERAXIS is associated with high relapse rates in esophageal candidiasis. […]

Conditions named in the indications of anidulafungin's FDA labels, with every medicine labeled for each:

Fungal infections

From other anidulafungin labels
Fungal infections: Esophageal Candidiasis ERAXIS is indicated for the treatment of esophageal candidiasis in adults [see Indications and Usage (1.3), Clinical Studies (14.2) ].

FDA pharmacologic class: Echinocandin Antifungal.

Source: FDA drug label (ERAXIS), NDA021632 (Vicuron Holdings), as published by Roerig, effective August 19, 2025 (SPL set a88d9010-55fb-4a02-baff-042cd27688ea), via openFDA; the full label on DailyMed

Is there a generic for anidulafungin (Eraxis)?

No generic anidulafungin is approved (Drugs@FDA, October 8, 2026).

2006 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What does the anidulafungin label say about other medicines?

The anidulafungin label names 5 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Amphotericin b	drug interactions	Liposome for Injection Administration of multiple doses of anidulafungin and liposomal amphotericin B to patients resulted in no significant alteration in the steady state pharmacokinetics of anidulafungin.
Cyclosporine	drug interactions	DRUG INTERACTIONS 7.1 Cyclosporine Administration of multiple doses of anidulafungin and cyclosporine to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug.
Rifampin	drug interactions	Administration of multiple doses of anidulafungin and rifampin to patients resulted in no significant alteration in the steady state pharmacokinetics of anidulafungin.
Tacrolimus	drug interactions	Administration of multiple doses of anidulafungin and a single-dose of tacrolimus to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug.
Voriconazole	drug interactions	Administration of multiple doses of anidulafungin and voriconazole to healthy subjects resulted in no significant alteration in the steady state pharmacokinetics of either drug.

Check anidulafungin against other medicines

What do FAERS reports show for anidulafungin?

The FDA Adverse Event Reporting System holds 1,600 reports that list anidulafungin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 688 are coded as a death and 770 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

Drug Ineffective (a use or a product term, not a reaction)384
Off Label Use (a use or a product term, not a reaction)186
Multiple Organ Dysfunction Syndrome173
Septic Shock128
Sepsis116
Pneumonia94
Candida Infection (a use or a product term, not a reaction)92
Pyrexia (named in the label)91

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as anidulafungin?

6 other medicines are given the same way (intravenous) and in the same FDA class as anidulafungin or labeled mainly for the same use (fungal infections), the same class first. Fungal infections lists all 33 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (intravenous)	Pharmacy cost	Shortage
Micafungin	Fungal infections	10 labelers	n/a	A presentation being discontinued
Caspofungin	Fungal infections	5 labelers	n/a	A presentation being discontinued
Voriconazole	Fungal infections	12 labelers	n/a	A presentation being discontinued
Fluconazole	Fungal infections	4 labelers	n/a	No current entry
Posaconazole	Fungal infections	7 labelers	n/a	A presentation being discontinued
Amphotericin b	Fungal infections	5 labelers	n/a	No current entry

Every medicine labeled for the same conditions as anidulafungin

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to anidulafungin: 6 medicines for the same use
Other echinocandin antifungals: the pharmacologic class, with prices and generics
Anidulafungin side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other